Abivax S.A.

NASDAQ:ABVX

Biotechnology

Healthcare
$82.10 -0.61%

-$0.62 today

Market cap
$7.19B
Beta
-0.20
P/E (TTM)
-18.1
EPS (TTM)
-$4.83
52W Low $5.69High $148.83

Volume 1.37M

Average 1.59M

ABVX Net Margin

Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.

Abivax S.A.NASDAQ: ABVX

Net Margin · Q2 FY2026 · quarter ended Jun 2026

Net margin not reported for Q2 FY2026

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
—— QoQ
Last fiscal yearDec 2025
—— YoY
Net Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3 years———
5 years——
10 years——

Net Margin history

Percent of revenue · from the income statement

No Net Margin data reported for this period type.

Net Margin vs competitors

How ABVX compares with its peers on the latest reported figures

ABVX Competitors Peer median
Net Margin for ABVX and competitors
Company Period LTM level YoY 3-year change
NRIXNurix Therapeutics, Inc.LTM Aug 202642.0% +334.5 pp+152.0 pp
ANABAnaptysBio, Inc.LTM Mar 2026-11.5% +114.2 pp+1245.7 pp
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 2026-112.0% +645.5 pp—
SYRESpyre Therapeutics, Inc.LTM Sep 2026-291.6% ——
RCUSArcus Biosciences, Inc.LTM Jun 2026-386.3% -269.5 pp+95.5 pp
ACRSAclaris Therapeutics, Inc.LTM Mar 2026-832.6% -100.2 pp-537.5 pp
IVAInventiva S.A.FY2025-7587.8% -5585.1 pp-7142.2 pp
AVTXAvalo Therapeutics, Inc.LTM Mar 2026-143627.1% -160183.1 pp-132411.6 pp
ABVXAbivax S.A.FY2025— ——
IMMXImmix Biopharma, Inc.FY2025— ——
ANNXAnnexon, Inc.FY2025— ——
Peer median (excluding ABVX) -338.9%-100.2 pp-221.0 pp

Competitors are the stored peer set for ABVX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue45.52M50.76M000
Gross Profit(45.52M)(50.76M)000
Gross Margin—————
Research & Development47.78M48.3M103.18M146.53M177.76M
Selling, General & Admin5.58M7.49M28.82M38.9M72.87M
Operating Expenses(4.12M)14.07M127.38M172.98M246.06M
Depreciation & Amortization302K485K707K1.1M1.07M
EBITDA(38.59M)(53.32M)(133.21M)(162.71M)(300.7M)
EBITDA Margin—————
Operating Income(41.4M)(64.84M)(127.38M)(172.98M)(246.06M)
Operating Margin—————
Interest Income002.77M8.96M5.75M
Interest Expense3.56M6.94M13.83M12.43M28.48M
Other Income / Expenses(1.05M)4.1M(20.36M)(3.26M)(84.2M)
Income Before Tax(42.45M)(60.74M)(147.74M)(176.24M)(330.25M)
Pre-Tax Margin—————
Income Tax Expense00005.85M
Net Income(42.45M)(60.74M)(147.74M)(176.24M)(336.1M)
Net Margin—————
EPS (Basic)(2.75)(3.18)(3.43)(2.80)(4.65)
EPS (Diluted)(2.75)(3.18)(3.43)(2.80)(4.65)
Weighted Avg Shares15.46M19.09M43.07M63.05M69.53M
Weighted Avg Shares (Diluted)15.46M19.09M43.07M63.05M69.53M

Abivax S.A.

NASDAQ:ABVX

Intrinsic Alpha fair value

Locked

Current Price

$82.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.